Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cold-EEZE continues brand transformation

This article was originally published in The Tan Sheet

Executive Summary

ProPhase Labs hires media solutions firm Women's Marketing Inc. to develop and implement multimedia campaigns for the Cold-EEZE and Kids-EEZE lozenge brands. Doylestown, Pa.-based ProPhase additionally announced details for its Kids-EEZE line extension of symptom-specific chews, including Allergy, Chest Congestion and Cough/Cold formulas. ProPhase already is revising its existing products' packaging and flavors (1"The Tan Sheet" May 24, 2010, In Brief). "We are excited to join with WMI to create a dynamic media campaign that will introduce our new and improved products to new consumers and reinvigorate our loyal customers," ProPhase CEO Ted Karkus said Sept. 7

You may also be interested in...

ProPhase pares costs, preps relaunches

The OTC firm, formerly known as Quigley, discontinues a candy product line and shutters a contract manufacturing facility, reducing first-quarter operating costs and expenses 51 percent to $2.2 million. ProPhase Labs' net sales in the January-March period also dropped 50.4 percent to $2 million, but its year-over-year net loss was halved to $1.1 million. Sales took a hit as retailer orders of cold and flu products, such as ProPhase's Cold-EEZE zinc lozenges, were front-loaded in fourth quarter 2009, according to CEO Ted Karkus. He added May 17 ProPhase is entering "a wonderful new phase," with redesigned packaging, a new mint frost Cold-EEZE flavor and the planned reintroduction of a Kids-EEZE non-liquid product line (1"The Tan Sheet" May 10, 2010, In Brief)

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts